Clinical Trials Using Carbon C11 Temozolomide

Clinical trials are research studies that involve people. The clinical trials on this list are studying Carbon C11 Temozolomide. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Carbon C 11 Temozolomide, PET, and MRI in Studying Tumor Blood Vessels in Patients with Recurrent Glioblastoma Receiving Bevacizumab and Temozolomide

    This pilot clinical trial studies carbon C 11 temozolomide, positron emission tomography (PET), and magnetic resonance imaging (MRI) in studying tumor blood vessels in patients with brain tumors that have come back and are receiving bevacizumab and temozolomide. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Since anti-VEGF agents also affect normal blood vessels in the brain, they may inhibit the way temozolomide is delivered to the tumor. Using a radioactive substance, such as carbon C 11 temozolomide, PET, and MRI may allow doctors to evaluate the changes in tumor blood flow, blood volume, and how receptive blood vessels are while also measuring how much temozolomide is in the brain.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts